51cg

Postgraduate research opportunities Application of ED to resonant acoustic mixer vs mechanochemical synthesis products

Apply

Key facts

  • Opens: Friday 13 November 2026
  • Number of places: 1
  • Duration: 36 months

Overview

This PhD project aims to develop a fundamental understanding of how pharmaceutical co-crystals form at the particle level by combining advanced crystallisation studies with state-of-the-art electron diffraction techniques.
Back to opportunity

Eligibility

Applicants must have an equivalent of a 2:1 degree and an IELTS score of an overall 6.5 with no individual element below 5.5

THE Awards 2019: UK University of the Year Winner
Back to opportunity

Project Details

This PhD project aims to develop a fundamental understanding of how pharmaceutical co-crystals form at the particle level by combining advanced crystallisation studies with state-of-the-art electron diffraction techniques. By directly observing structural transformations during co-crystal formation, the project seeks to identify transient and intermediate phases that have remained inaccessible to conventional characterisation methods, providing new insight into the mechanisms that govern solid-state reactivity.

Pharmaceutical co-crystals represent an increasingly important strategy for modifying the physicochemical properties of active pharmaceutical ingredients (APIs) without altering their molecular structure. Unlike salt formation, co-crystallisation does not require the presence of an ionisable functional group, greatly expanding the range of materials that can be engineered to optimise properties such as solubility, dissolution rate, stability, manufacturability, and bioavailability.

Despite significant advances in co-crystal design and screening, our current understanding of co-crystal formation remains limited. Most mechanistic models are based on analysis of the final crystalline product, providing only indirect evidence of the processes occurring during transformation. Two principal formation mechanisms have been proposed: direct molecular rearrangement at particle interfaces and dissolution-mediated pathways involving transient intermediate phases. However, experimental evidence distinguishing between these mechanisms remains scarce because conventional characterisation techniques, such as X-ray powder diffraction (XRPD), typically provide ensemble-averaged information and may fail to detect short-lived or localised structural intermediates.

Recent developments in electron diffraction provide an unprecedented opportunity to overcome these limitations. By investigating individual particles with nanometre-scale spatial resolution, electron diffraction enables the structural characterisation of crystalline domains far below the detection limits of conventional diffraction methods. This project will use electron diffraction to directly probe the transformation of reactants into co-crystal products, revealing whether transient phases, structural defects, or metastable intermediates exist during co-crystal formation and how these influence the final solid form.

Building upon expertise in pharmaceutical crystallography, solid-state chemistry, and advanced diffraction methods, this project will investigate a range of pharmaceutical co-crystal systems to establish fundamental relationships between formation pathway, particle-scale structure, and final material properties.

Core objectives

  • investigation of co-crystal formation mechanisms in pharmaceutical materials using electron diffraction and complementary solid-state characterisation methods
  • identification and structural characterisation of transient phases, intermediates, and defect-rich regions formed during crystallisation
  • comparison of direct solid-state and dissolution-mediated co-crystallisation pathways
  • correlation of particle-level structural evolution with bulk phase behaviour observed by conventional diffraction techniques
  • development of mechanistic models describing co-crystal nucleation, growth, and transformation processes
  • establishment of design principles to improve the rational development and manufacture of pharmaceutical co-crystals

Adaptable themes

We currently have a diverse range of research directions that can be tailored to the interests of the PhD candidate, including:

  • pharmaceutical co-crystal formation and solid-state reactivity
  • mechanochemical and solvent-assisted co-crystallisation
  • time-resolved and in situ studies of crystallisation processes
  • electron diffraction for pharmaceutical materials characterisation
  • identification and characterisation of metastable solid forms
  • crystallisation mechanisms in molecular and pharmaceutical solids
  • structure-property relationships in pharmaceutical co-crystals
  • integration of electron diffraction with crystallographic and spectroscopic techniques

Research significance

A fundamental understanding of co-crystal formation remains one of the major challenges in pharmaceutical solid-state science. By providing direct experimental evidence of structural changes occurring during co-crystallisation, this project will address important gaps in current mechanistic models and help explain why some co-crystals form readily while others are difficult to obtain or reproduce.

The outcomes will contribute to the rational design of pharmaceutical solid forms and support the development of more efficient crystallisation and manufacturing strategies. More broadly, the methodologies developed during the project will establish electron diffraction as a powerful tool for investigating crystallisation pathways in molecular materials, extending beyond pharmaceuticals to a wide range of functional solids.

Techniques you will learn

  • electron diffraction data collection and structure determination
  • advanced crystallographic analysis of molecular materials
  • single-crystal and powder X-ray diffraction
  • co-crystal screening and crystallisation methods
  • mechanochemical synthesis and solvent-assisted grinding
  • in situ and time-resolved crystallisation studies
  • thermal analysis (DSC, TGA)
  • spectroscopic characterisation (Raman and infrared spectroscopy)
  • microscopy and particle-scale materials characterisation
  • scientific programming and crystallographic data analysis
Back to opportunity

Funding details

While there is no funding in place for opportunities marked "unfunded", there are lots of different options to help you fund postgraduate research. Visit funding your postgraduate research for links to government grants, research councils funding and more, that could be available.

Back to opportunity

Supervisors

Dr Oswald

Dr Iain Oswald

Reader
51cg Institute of Pharmacy and Biomedical Sciences

View profile
Back to course

Apply

Number of places: 1

To read how we process personal data, applicants can review our 'Privacy Notice for Student Applicants and Potential Applicants' on our Privacy notices' web page.

SIPBS (Pharmacy)

Programme: SIPBS (Pharmacy)

PhD
full-time
Start date: Oct 2026 - Sep 2027